The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

David Krall, a director at Harmonic Inc . (NASDAQ:HLIT), a $1.15 billion market cap company with strong liquidity and moderate debt levels, has made a significant acquisition of the company's common ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Natan, President and CEO of Harmonic Inc . (NASDAQ:HLIT), acquired a substantial number of shares in the company. The purchases consisted of 7,780 shares of common stock, with a total value of $75,060 ...

Harmonic Inc. (NASDAQ:HLIT – Get Free Report) reached a new 52-week low during trading on Tuesday after Rosenblatt Securities ...

Harmonic (HLIT) delivered earnings and revenue surprises of 21.62% and 4.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that BenNatan purchased 7,780 shares of Harmonic. The total transaction amounted to $75,060. Harmonic ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

Harmonic's shares fell after the company's earnings forecast for the current quarter and the year fell short of analysts' expectations. The stock slid 31%, to $7.69, in post-market trading Monday.

Harmonic expects full-year earnings in the range of 43 cents to 68 cents per share, with revenue ranging from $585 million to $645 million. This story was generated by Automated Insights ( ...